Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?

Leukemia volume 31, pages 266–267 (2017)Cite this article

Subjects

For more than a decade, the prediction of treatment response to first-line imatinib (IMA) prior to IMA administration has attracted increasing interest since it became apparent that clear personalized treatment regimens have clinical benefits, especially in the current era of alternative therapies. Early, fast and accurate stratification of patients with chronic myeloid leukaemia (CML) to IMA responders and non-responders may guide therapeutical decisions, resulting in considerable long-term benefit for CML patients.

Based on controversial results reported in a significant number of studies, it would appear that there is still no definite, independent biomarker that can reliably predict primary resistance to IMA therapy even after a decennium of intensive research aimed at finding predictive indicators of CML, such as alterations in the expression or functional activity of influx and efflux transporters,1, 2, 3, 4, 5, 6 IMA plasma concentration,7, 8 and IMA intracellular concentration.8 It is important to note that this failure often stems from the complexity of the laboratory assays employed in these studies, which generate conflicting results that complicate the translation of even strong predictors into clinical practice.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Eadie LN, Dang P, Saunders VA, Yeung DT, Osborn MP, Grigg AP et al. The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. Leukemia 2016; e-pub ahead of print 15 July 2016; doi:10.1038/leu.2016.179.

    Article  Google Scholar 

  2. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE . Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008; 83: 258–264.

    Article  CAS  Google Scholar 

  3. White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010; 28: 2761–2767.

    Article  CAS  Google Scholar 

  4. Razga F, Racil Z, Machova Polakova K, Buresova L, Klamova H, Zackova D et al. The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia. Int J Hematol 2011; 94: 303–306.

    Article  Google Scholar 

  5. Racil Z, Razga F, Buresova L, Jurcek T, Dvorakova D, Zackova D et al. The assessment of human organic cation transporter 1 (hOCT1 mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population. Am J Hematol 2010; 85: 525–528.

    Article  CAS  Google Scholar 

  6. Racil Z, Razga F, Polakova KM, Buresova L, Polivkova V, Dvorakova D et al. Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1 mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types. Leuk Lymphoma 2011; 52: 331–334.

    Article  CAS  Google Scholar 

  7. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109: 3496–3499.

    Article  CAS  Google Scholar 

  8. Racil Z, Razga F, Klamova H, Voglova J, Belohlavkova P, Malaskova L et al. No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia. Hematol Oncol 2014; 32: 87–93.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the Slovak Research and Developmental Agency under Contract No. APVV-15-0215 and by VEGA Grant No. 2/0094/15. Rázga is receiving support within the SASPRO Programme (Project No. 0057/01/02) co-funded by the European Union and the Slovak Academy of Sciences.

Author information

Author notes

  1. V Némethová and F Rázga: These authors equally contributed to this work.

Authors and Affiliations

  1. Polymer Institute, SAS, Bratislava, Slovakia

    V Némethová & F Rázga

Authors
  1. V Némethová
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Rázga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F Rázga.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Némethová, V., Rázga, F. Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?. Leukemia 31, 266–267 (2017). https://doi.org/10.1038/leu.2016.266

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2016.266

This article is cited by

Search

Advanced search

Quick links